Cachet Pharmaceutical's low P/E ratio may be due to expectations of underperformance. Declining earnings and potential for further P/E drop could disappoint shareholders.
The company's high liabilities and decreasing ROCE are worrisome. Reinvestment has not led to significant sales growth. These trends are not typical for multi-baggers, suggesting investors may need to look elsewhere.
Cachet Pharmaceuticalに関するコメント
まだコメントはありません